InterVivo Solutions

Recent News

  • InterVivo Solutions Provides Update on Cooperative Psychedelics Evaluation Platform (COPE) - Names Drs. Inés De Lannoy and Lilia Magomedova to Lead Bioanalytical Platform Development

    Toronto, Ontario--(Newsfile Corp. - June 12, 2021) - InterVivo Solutions (IVS) today announced availability of its first data set as part of the COPETM program. The program, launched in March, in collaboration with Mindset Pharma Inc. (CSE: MSET) aims to create the world's first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including Psilocybin, LSD, DMT, and 5-MeO-DMT amongst others. Preliminary data released today focused on Psilocybin/Psilocin and demonstrate that the clinical exposure levels reported in humans...

    2021-06-12 9:00 AM EDT
  • InterVivo Solutions and Mindset Pharma to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("COPE")

    Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - InterVivo Solutions Inc. ("InterVivo" or "IVS" or the "Company"), a leading Canadian contract research organization providing preclinical in vivo research services that enable the pharmaceutical and nutraceutical industries to develop new products and therapies for neuropsychiatric and neurological diseases, is pleased to announce that it has entered a co-development agreement with Mindset Pharma Inc. (CSE: MSET) ("Mindset") to co-develop a new translational testing platform that will set the performance standards for breakthrough...

    2021-03-23 7:00 AM EDT
  • InterVivo Solutions Issued Institutional Cannabis Research License by Health Canada

    Toronto, Ontario--(Newsfile Corp. - February 4, 2021) - InterVivo Solutions Inc. ("InterVivo" or the "Company"), a leading Canadian contract research organization providing preclinical in vivo research services that enable the pharmaceutical and nutraceutical industries to develop new products and therapies for neuropsychiatric and neurological diseases, is pleased to announce that it has been issued an Institution-wide Research License from Health Canada under the Cannabis Act and Cannabis Regulations.The Institution-wide Research License (IRL) enables InterVivo to conduct multiple studies across all...

    2021-02-04 3:45 PM EST